Quantifying The Economic Burden Of IBS-D
As the industry shifts from volume to value based models, it is becoming necessary for Pharmaceutical companies to demonstrate the value their brands deliver through outcomes and e ...
Decision Science Asset Diversification Versus Concentration
The pharmaceutical industry continues to undergo tremendous changes. The questions for executives are how do these changes affect the direction of investments in new decision scien ...
Achieving Sales Operations Excellence With Intelligent Roster Management
Effective roster management has long been an overlooked topic in Pharma commercial operations. At any point in time, it is critical for the Sales Operations business processes to h ...
The Reasons for and Solutions to Chronic Drug Shortages in the United States
This white paper will briefly address the questions and present the key reasons for and solutions to the existence of chronic drug shortages in the US. It will also discuss the rol ...
Pricing and Market Effects of Biosimilar Entry in the US
This white paper will provide insights into key questions as they pertain to the entry of biosimilars in the US market, pricing and market effects and the future of biosimilars in ...
The Importance of Governance in Your Incentive Compensation Program
In this white paper, we address the importance of IC Governance, its team make up, roles and responsibilities. We also go into the details of governing best practices towards plan ...
Designing Incentive Compensation Plans for Specialty Products
The focus of this white paper is to highlight key challenges in designing IC plans for promoting specialty drugs by a pharmaceutical sales force and recommended best practices when ...
Sales Analytics and Big Data Developments Needed Now to Address Sales Force Issues
The biopharmaceutical industry is undergoing significant changes. Most importantly, there is a shift toward greater company R&D focus on and launching of specialty medicines. W ...
State Of Commercial Excellence 2017 – Part 1
Axtria recently launched a Commercial Excellence Survey to better understand the readiness of commercial organizations when facing these changing market realities. The survey inclu ...
As the coronavirus (COVID-19) global pandemic unfolds, we would like to share our plans to conduct our business seamlessly while giving utmost priority to the health and well-being of our employees and our ecosystem of customers, vendors, and partners.
Our hearts go out to anyone directly or indirectly impacted by this pandemic. We are inspired by the selfless service of healthcare workers, first responders, and other professionals who continue to serve the people in need.
Our two main priorities at Axtria include:
We pride ourselves on being a highly customer-centric company. Rest assured, we will continue to help achieve all business goals by ensuring that our team is fully equipped to stand in support. Our integrated cloud platforms enable global commercial organizations to work seamlessly and automate manual processes. They are built from the ground up to support teams that need to work remotely.
To ensure health and safety, we have asked our employees globally to follow the guidelines of the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and maintain social distancing, work from home, and swap in-person meetings with phone and video calls. Assuredly, our employees are well-versed in remote work, given our technology infrastructure, ongoing training, and existing processes. We have also rescheduled all in-person events in the coming weeks to digital platforms. Doing so allows us to suspend all unnecessary business travel and large gatherings.
Lastly, we will continue monitoring the COVID-19 data and will make operational adjustments as needed. As a data analytics company, we are committed to making data-driven decisions in every aspect of the business. We shall continue doing so using the most reliable data - from the WHO, the CDC, data-based case tracking via Johns Hopkins University (JHU), as well as through national and local administrations.
As always, Axtria will continue to provide our unwavering support. In dealing with the present circumstances, we will continue employing every effort to deliver uninterrupted services.
Further, you can bank on us to alert you of any protocol changes while encouraging you to approach us with your feedback and queries – not just as business partners, but as valued friends.
On behalf of all Axtrians, I wish you and your families safety and good health during these trying times.
We are isolated but united!
All the best,